-
Malate in TCA Cycle Research: Protocols and Translational In
2026-05-30
Malate ((S)-2-hydroxysuccinic acid) serves as a versatile tricarboxylic acid cycle intermediate, enabling precise dissection of mitochondrial bioenergetics and metabolic reprogramming in disease models. This article translates emerging experimental workflows—rooted in recent cancer metabolism research—into actionable protocols and troubleshooting strategies for malate use in vitro and in vivo.
-
Efficient iPSC Differentiation to Retinal Ganglion Cells via
2026-05-29
This study introduces a reproducible protocol using dual SMAD and Wnt inhibition to efficiently differentiate human induced pluripotent stem cells (iPSCs) into retinal ganglion cells (RGCs) with high purity. The findings address critical variability issues in stem cell-derived RGC generation, offering new potential for modeling glaucoma and advancing regenerative therapies.
-
ATRX-Deficient Glioma Sensitivity to RTK and PDGFR Inhibitor
2026-05-29
The reference study demonstrates that high-grade glioma cells lacking ATRX are significantly more sensitive to multi-targeted RTK and PDGFR inhibitors. These findings suggest ATRX mutation status should inform therapeutic strategies and clinical trials involving angiokinase inhibitors.
-
Sisomicin: Broad-Spectrum Aminoglycoside Antibiotic for Rese
2026-05-28
Sisomicin is a potent aminoglycoside antibiotic that inhibits bacterial protein synthesis through 30S ribosomal binding. It demonstrates strong activity against both Gram-negative and Gram-positive pathogens, making it valuable for in vitro antibacterial testing and translational infection research. APExBIO supplies Sisomicin (SKU: BA1199) for precision experimental workflows.
-
Angiotensin Peptides Enhance SARS-CoV-2 Spike–Receptor Bindi
2026-05-28
Oliveira et al. (2025) reveal that naturally occurring angiotensin peptides can significantly increase the binding affinity of the SARS-CoV-2 spike protein to its host cell receptors, particularly AXL. This finding bridges cardiovascular peptide biology and viral pathogenesis, suggesting new research directions in COVID-19 susceptibility and therapeutic targeting.
-
Nintedanib (BIBF 1120): Precision Angiokinase Inhibition Wor
2026-05-27
Nintedanib (BIBF 1120) empowers researchers with robust, reproducible antiangiogenic and antifibrotic workflows, delivering nanomolar inhibition of VEGFR, FGFR, and PDGFR pathways. This guide bridges foundational protocols with advanced troubleshooting, highlighting innovations for ATRX-deficient tumor and fibrosis research.
-
2-Deoxy-D-glucose: Precision Glycolysis Inhibition in Tumor
2026-05-27
Explore how 2-Deoxy-D-glucose (2-DG) enables precision targeting of tumor immunometabolism, with nuanced insights into macrophage metabolic reprogramming and glycolysis inhibition in cancer research. Discover advanced protocols, emerging synergies, and practical assay guidance.
-
Phosphatase Inhibitor Cocktail 1: Preserving Phosphorylation
2026-05-26
Phosphatase Inhibitor Cocktail 1 (100X in DMSO) elevates phosphoproteomic workflows by arresting protein dephosphorylation with unrivaled efficiency. Its robust, DMSO-based formulation enables reproducible phosphorylation state preservation across diverse tissue and cell lysates—critical for advanced signal transduction research and high-fidelity Western blot assays.
-
Cy5 Hydrazide (Non-Sulfonated): Precision in Advanced Carbon
2026-05-26
Explore how Cy5 hydrazide, a carbonyl-reactive fluorescent dye, enables precision labeling of aldehyde and ketone groups in biomolecules. This guide delivers advanced scientific insights and practical protocols, positioning Cy5 hydrazide for next-generation protein carbonylation studies.
-
Bestatin (Ubenimex): Redefining Aminopeptidase Inhibition in
2026-05-25
Explore how Bestatin (Ubenimex) empowers advanced cell signaling research, from dissecting aminopeptidase specificity to optimizing apoptosis assays and multidrug resistance studies. This article provides a unique, protocol-driven perspective grounded in leading-edge scientific evidence.
-
HDAC8-Driven AKT Activation in MEK1/2 Inhibitor-Resistant Tu
2026-05-25
This study elucidates how HDAC8 promotes resistance to MEK1/2 inhibition in NRAS/BRAF-mutant cancer cells via upregulation of PLCB1 and suppression of DESC1, leading to AKT pathway activation. These findings highlight new molecular targets for overcoming adaptive resistance in targeted cancer therapy.
-
BMS 599626 Dihydrochloride: Precision EGFR and ErbB2 Inhibit
2026-05-24
BMS 599626 dihydrochloride enables reproducible, selective inhibition of EGFR and ErbB2 signaling, advancing breast and lung cancer research and senescence studies. This article details optimized workflows, protocol parameters, and troubleshooting strategies, highlighting APExBIO’s role in providing high-purity reagents that accelerate translational discoveries.
-
Epigenetic Mcl-1 Targeting Plus BCL-XL Inhibition in Gliobla
2026-05-23
This study reveals that epigenetic suppression of Mcl-1, when paired with BCL-XL/BCL-2 inhibition, produces synthetic lethality and robust apoptosis in glioblastoma models. The approach leverages super-enhancer disruption to sensitize tumors resistant to conventional apoptosis induction routes, offering a new therapeutic angle for treatment-refractory brain cancers.
-
Gramine Induces Ferroptosis in TNBC via CUL3–MTDH Ubiquitina
2026-05-22
The reference study identifies Gramine as a potent ferroptosis inducer that suppresses triple-negative breast cancer (TNBC) by targeting the CUL3–MTDH ubiquitination pathway. These findings provide mechanistic insight into ferroptosis regulation in TNBC and support Gramine's role as a tool compound for cancer biology research.
-
Nintedanib (BIBF 1120): Applied Workflows for Cancer Researc
2026-05-22
Nintedanib (BIBF 1120) empowers translational researchers to precisely dissect angiogenesis and tumor progression in complex disease models. This article reveals practical workflows, troubleshooting strategies, and experimental insights that maximize the value of APExBIO’s validated triple angiokinase inhibitor in both cell-based and in vivo systems.